These protease-activated peptides (PAP7, PAP9, PAP11, PAP13, PAP15) broadly cover metallo, serine and aspartic protease activities (Supplementary Fig. 7e), and were specifically cleaved by tumour tissue homogenates ex vivo with highly predicted disease classification power, and thus were incorporated into the panel of DNA-SUBs for in vivo validation (Fig. 4c and Supplementary Figs. 8 and 9a). Here, ACBD3 is linked to neoplasm.